These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 18543703

  • 1. [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Dokekias AE, Galiba FO, Bokilo AD, Ntsimba P, Nsitou MB, Malanda F, Basseila GB.
    Bull Soc Pathol Exot; 2008 Apr; 101(2):109-12. PubMed ID: 18543703
    [Abstract] [Full Text] [Related]

  • 2. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C, Tchatchueng Mbougua JB, Ngom Guèye NF, Etard JF, Diouf A, Landman R, Molinari N, Girard PM, Sow PS, Ndoye I, Delaporte E, ANRS 1215/1290 Study Group.
    Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
    [Abstract] [Full Text] [Related]

  • 3. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E, GESIDA 3903 Team.
    Clin Infect Dis; 2008 Oct 15; 47(8):1083-92. PubMed ID: 18781872
    [Abstract] [Full Text] [Related]

  • 4. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 5. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D, OzCombo 2 investigators.
    HIV Clin Trials; 2002 Jul 28; 3(3):177-85. PubMed ID: 12032876
    [Abstract] [Full Text] [Related]

  • 6. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.
    J Infect Dis; 2010 Nov 15; 202(10):1529-37. PubMed ID: 20942650
    [Abstract] [Full Text] [Related]

  • 7. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    Kyaw NL, Thanachartwet V, Kiertiburanakul S, Desakorn V, Chamnanchanunt S, Chierakul W, Manosuthi W, Pitisuttithum P, Sungkanuparph S.
    Southeast Asian J Trop Med Public Health; 2013 Mar 15; 44(2):232-43. PubMed ID: 23691633
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 15; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 10. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA.
    AIDS; 2000 Jun 16; 14(9):1171-80. PubMed ID: 10894281
    [Abstract] [Full Text] [Related]

  • 11. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V.
    HIV Med; 2008 May 16; 9(5):317-21. PubMed ID: 18331562
    [Abstract] [Full Text] [Related]

  • 12. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.
    J Acquir Immune Defic Syndr; 2009 May 01; 51(1):37-46. PubMed ID: 19282782
    [Abstract] [Full Text] [Related]

  • 13. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
    Zhou HY, Zheng YH, Zhang CY, Chen J, He Y, Ding PP, Li H.
    Viral Immunol; 2007 Feb 15; 20(1):180-7. PubMed ID: 17425432
    [Abstract] [Full Text] [Related]

  • 16. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F, VIRGO Study Team.
    Antivir Ther; 1999 Feb 15; 4 Suppl 3():83-4. PubMed ID: 16021876
    [Abstract] [Full Text] [Related]

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 15; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 18. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 19. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Mar 10; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 20. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct 10; 13(73):180-2. PubMed ID: 15499699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.